Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)

Technology appraisal guidance
Published: 27 October 2010
nice.org.uk/guidance/ta207
Contents

Advice ........................................................................................................................................................................ 3
Background.............................................................................................................................................................. 4
Information ............................................................................................................................................................ 5
Related NICE guidance ............................................................................................................................................... 5
Advice

NICE is unable to recommend the use in the NHS of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma because no evidence submission was received from the manufacturer or sponsor of the technology.
**Background**

The manufacturer of temsirolimus (Wyeth) was invited to submit evidence for this single technology appraisal (STA) in November 2009.

In January 2010, the manufacturer informed NICE that it would not be making an evidence submission. The manufacturer subsequently confirmed this in August 2010. Given the rarity of the condition, the complex clinical management of mantle cell lymphoma and the large number of comparator regimens used in the single randomised clinical trial, the manufacturer did not believe that an adequate assessment of the clinical and cost effectiveness of temsirolimus would be possible.

NICE has therefore terminated this single technology appraisal.
NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma. If, after doing this, organisations still wish to consider the use of temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma, they should follow the advice set out in 'Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance' which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.

NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.

*Related NICE guidance*

There is no related NICE guidance.

*Accreditation*